LLY·Healthcare·Pharma
Eli Lilly Jaypirca Approval +6.8% as CHMP Backs CLL Use
Can Eli Lilly Jaypirca Approval turn a regulatory win into a lasting oncology growth engine for investors?
Healthcare
LLY·Healthcare·Pharma
PFE·Healthcare·Pharma
Pfizer Lung Cancer Trial Sends Warning on Oncology Pivot
Can Pfizer’s lung cancer setback stay contained to one trial, or is it an early warning for its broader oncology…
UNH·Healthcare
UnitedHealth Regulation: $111B Revenue Meets New Scrutiny
Can UnitedHealth’s strong earnings momentum survive the growing weight of DOJ, FTC, and Medicare scrutiny?
PFE·Healthcare·Pharma
Pfizer CFO Transition -2.9%: Stock Drops After CFO Exit
Can Pfizer convince Wall Street this CFO change is about continuity, not a deeper warning on execution and growth?
NVO·Healthcare·Pharma
Novo Nordisk Wegovy Hits 3M U.S. Prescriptions in 22 Weeks
Has Novo Nordisk Wegovy just delivered the prescription surge that forces Wall Street to rethink the entire obesity trade?
MRNA·Healthcare·Biotech
Moderna Flu Vaccine: FDA Briefing Sets Up Key Vote
Will Moderna Flu Vaccine finally clear the FDA hurdle, or is Wall Street getting ahead of itself again?
NVO·Healthcare·Pharma
Novo Nordisk Wegovy Faces a Warning in the Obesity Race
Can Novo Nordisk Wegovy regain momentum fast enough to challenge Eli Lilly before the next wave of obesity drugs resets…
LLY·Healthcare·Pharma
Eli Lilly Acquisition Signals Pain Drug Boom Beyond GLP-1
Can Eli Lilly’s latest deal prove the company is more than a one-theme GLP-1 growth story?
MRNA·Healthcare·Biotech
Moderna Restructuring +6.3% as FDA Momentum Builds
Can Moderna Restructuring turn an mRNA pioneer into a true multi-product biotech contender before its next major FDA test?
MRK·Healthcare·Pharma
Merck Protillion Collaboration Sends MRK Soaring 15%
Can the Merck Protillion Collaboration really help MRK outrun its post-Keytruda patent fears and justify Wall Street’s sudden excitement?